Viridian Therapeutics Inc (NAS:VRDN)
$ 19.45 -0.38 (-1.92%) Market Cap: 1.54 Bil Enterprise Value: 1.03 Bil PE Ratio: 0 PB Ratio: 2.97 GF Score: 61/100

Viridian Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 03:30PM GMT
Release Date Price: $22.81 (-4.24%)
Lalita Sundarrajan J.P. Morgan Chase Co.;Analyst

Good morning, everyone. My name is Lalita Sundarrajan. And it's my pleasure to introduce Viridian Therapeutics speakers for today, President and CEO, Steve Mahoney, joined onstage by our Chief Business Officer, Shan Wu. With that, Steve, I'll turn it over to you.

Stephen Mahoney
Viridian Therapeutics Inc - President, Chief Executive Officer, Director

Thank you very much, Lalita. Good morning, everyone, and thank you for joining us. I am pleased to be here today to tell you about Viridian. We are very excited about 2024, the year ahead.

Viridian is building what we believe to be a world-class portfolio in two key areas: thyroid eye disease with a potential best-in-class therapy for thyroid eye disease and a portfolio of FcRns that are differentiated from and improved upon current products and those that are also in development.

Before we get started, I'd like to mention that we will be making forward-looking statements today. They are subject to risks and uncertainties, and we refer you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot